These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27171020)

  • 1. Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy.
    Chen BB; Hsu CY; Yu CW; Liang PC; Hsu C; Hsu CH; Cheng AL; Shih TT
    Radiology; 2016 Nov; 281(2):454-464. PubMed ID: 27171020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.
    Chen BB; Hsu CY; Yu CW; Hou HA; Liu CY; Wei SY; Chou WC; Tien HF; Shih TT
    Radiology; 2011 Mar; 258(3):821-31. PubMed ID: 21212370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study.
    Lee SH; Hayano K; Zhu AX; Sahani DV; Yoshida H
    Acad Radiol; 2015 Nov; 22(11):1344-60. PubMed ID: 26211553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density.
    Chen J; Chen C; Xia C; Huang Z; Zuo P; Stemmer A; Song B
    Abdom Radiol (NY); 2018 Jun; 43(6):1393-1403. PubMed ID: 28939963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
    Choi SY; Kim SH; Park CK; Min JH; Lee JE; Choi YH; Lee BR
    Radiology; 2018 Mar; 286(3):897-908. PubMed ID: 29166246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
    Stocker D; Hectors S; Bane O; Vietti-Violi N; Said D; Kennedy P; Cuevas J; Cunha GM; Sirlin CB; Fowler KJ; Lewis S; Taouli B
    Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.
    Liang PC; Ch'ang HJ; Hsu C; Chen LT; Shih TT; Liu TW
    Hepatol Int; 2015 Apr; 9(2):258-68. PubMed ID: 25788178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma.
    Chen BB; Hsu CY; Yu CW; Liang PC; Hsu C; Hsu CH; Cheng AL; Shih TT
    Eur Radiol; 2017 Jul; 27(7):3069-3079. PubMed ID: 27957638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI.
    Taouli B; Johnson RS; Hajdu CH; Oei MT; Merad M; Yee H; Rusinek H
    AJR Am J Roentgenol; 2013 Oct; 201(4):795-800. PubMed ID: 24059368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid-enhanced MR Imaging and Dynamic CT.
    Choi SH; Lee SS; Kim SY; Park SH; Park SH; Kim KM; Hong SM; Yu E; Lee MG
    Radiology; 2017 Mar; 282(3):771-781. PubMed ID: 27797675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
    Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
    Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
    Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
    Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma: Diagnostic Accuracy of Gadoxetic Acid-enhanced MR Imaging.
    Kim JH; Lee JM; Yoon JH; Lee DH; Lee KB; Han JK; Choi BI
    Radiology; 2016 Jun; 279(3):773-83. PubMed ID: 26780538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Hepatic Perfusion Using GRASP MRI: Bringing Liver MRI on a New Level.
    Weiss J; Ruff C; Grosse U; Grözinger G; Horger M; Nikolaou K; Gatidis S
    Invest Radiol; 2019 Dec; 54(12):737-743. PubMed ID: 31206392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience.
    Hectors SJ; Wagner M; Besa C; Huang W; Taouli B
    Contrast Media Mol Imaging; 2018; 2018():5638283. PubMed ID: 30402045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.
    Kim HD; Lim YS; Han S; An J; Kim GA; Kim SY; Lee SJ; Won HJ; Byun JH
    Gastroenterology; 2015 Jun; 148(7):1371-82. PubMed ID: 25733098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of Dynamic Contrast-enhanced and Diffusion-weighted MR Imaging in the Detection of Pathologic Complete Response in Cervical Cancer after Neoadjuvant Therapy: A Retrospective Observational Study.
    Jalaguier-Coudray A; Villard-Mahjoub R; Delouche A; Delarbre B; Lambaudie E; Houvenaeghel G; Minsat M; Tallet A; Sabatier R; Thomassin-Naggara I
    Radiology; 2017 Aug; 284(2):432-442. PubMed ID: 28301309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.